KRAS and colorectal carcinoma: While the resistance of KRAS‐mt CRC to anti‐EGFR therapy can be explained by the constitutive activation of the MAPK pathway [13], the mechanisms of resistance to nontargeted therapies (such as CRT) remain largely unexplored.